Mylan picks 3M to manufacture its generic Advair inhaler for U.K. market

Mylan ($MYL) said on Monday that it had started selling in the U.K. its generic of GlaxoSmithKline's ($GSK) asthma treatment Seretide Evohaler, known better in the U.S. as Advair. Mylan said the inhalers will be assembled and packaged for it by 3M Drug Delivery Systems at the 3M ($MMM) manufacturing facility in Loughborough, U.K. There are already other generics in the U.K. of the blockbuster, which in 2013 turned in sales of $8.6 billion. The growing competition has taken a big bite out of GSK's revenues, leading it to make layoffs in the U.S. Release | More

Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)